Onconetix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Onconetix, Inc. (ONCO) on March 23, 2026, regarding a corporate action effective March 25, 2026. The filing details the implementation of a reverse stock split previously authorized by stockholders at a special meeting on February 3, 2026.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes.
Material Changes
- Reverse Stock Split Execution: The Board fixed a 1-for-5 reverse stock split ratio on March 6, 2026. The split became effective at 12:01 a.m. Eastern Time on March 25, 2026.
- Share Count Reduction: The number of issued and outstanding common shares decreased from 3,464,686 to 692,927.
- Trading Adjustments: Common stock began trading on a split-adjusted basis on March 25, 2026, under a new CUSIP number (68237Q302).
- Fractional Shares: No fractional shares were issued. Stockholders entitled to fractional shares received cash payments based on the closing sale price on March 24, 2026.
- Equity Awards: Proportional adjustments were made to shares issuable upon exercise or conversion of equity awards, convertible preferred stock, and warrants, including adjustments to exercise prices.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosure that the description of the Amendment is qualified by reference to the full text filed as Exhibit 3.1.
Investor Verification Checklist
- Verify the new CUSIP number (68237Q302) for trading purposes.
- Confirm the adjusted share count and exercise prices for any held options, warrants, or convertible securities.
- Check brokerage statements for the receipt of cash payments in lieu of fractional shares.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for complete legal terms.